1 / 17

Oxygen Sensing, Homeostasis, and Disease Semenza. NEJM , August 2011, 246: 6

Oxygen Sensing, Homeostasis, and Disease Semenza. NEJM , August 2011, 246: 6. Amelia Crawford PA-S2. Hypoxia Inducible Factor 1. All nucleated cells in the human body respond to hypoxia HIF-1 plays a critical role in the cells’ response.

corine
Télécharger la présentation

Oxygen Sensing, Homeostasis, and Disease Semenza. NEJM , August 2011, 246: 6

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Oxygen Sensing, Homeostasis, and DiseaseSemenza.NEJM, August 2011, 246: 6 Amelia Crawford PA-S2

  2. Hypoxia Inducible Factor 1 • All nucleated cells in the human body respond to hypoxia • HIF-1 plays a critical role in the cells’ response. • When oxygen availability is decreased, HIF-1 regulates the expression of genes that mediate adaptive responses by cells

  3. Hypoxia Inducible Factor 1 • HIF-1 is composed of a beta and an alpha subunit. • The alpha subunit is oxygen regulated • In aerobic conditions, HLF-1 (alpha) is normally hydroxylated and then degraded by proteasomes • In hypoxic conditions, the hydroxylation is inhibited, HIF-1 (alpha) accumulates, and it up regulates several genes to promote survival in cells • Stimulates erythropoetin, angiogenesis, & glycolytic metabolism

  4. HIF-1

  5. HIF-1 and Cardiovascular Disease • Atherosclerotic disease causes stenosis of vessels and results in decreased blood flow distally. • Decreased blood flow →decreased O2 supply • In studies with mice in which the femoral artery was ligated, induction of HIF-1 resulted in increased activation of VEGF, which eventually caused angiogenesis and reperfusion of the limb via the production of collateral blood flow. • The normal adaptive vascular response is impaired by aging & DM—major causes of CAD and PVD

  6. HIF-1 and Cardiovascular Disease • VEGF other factors promote angiogenesis by stimulating vascular cells and also by mobilizing bone-marrow derived angiogenic cells (BMDACs) • BMDACs = myeloid cells that stimulate vascular remodeling. • In order to initiate a vascular response, they must mobilized from bone marrow, enter the peripheral blood, and be retained within the ischemic tissue by adhering to the vascular endothelium. • Aging results in the loss of ischemia induced expression of angiogenic factors and BMDAC mobilization and consequently, angiogenesis and reperfusion are decreased.

  7. HIF-1 and Cardiovascular Disease • HIF-1α induction occurs early in the course of a MI • In studies with mice with an over expression of HIF-1αthat underwent coronary artery ligation, there was a smaller infarct size, improved cardiac function, and increased capillary density. • Collateral vessels are routinely identified in 2/3 of patients with critical coronary artery disease that is sufficient to cause angina. • Patients with a collateral blood supply that eventually suffered a MI also had smaller infarcts and were more likely to survive than those without a collateral vessels. • HIF-1 also helps the heart to survive episodes of O2 deprivation by inducing glycolytic metabolism & adenosine production

  8. HIF-1 and Cardiovascular Disease • Pharmacologic agents that activate HIF-1 are a therapeutic target in treating patients with CAD and PVD (Gene therapy) • In preclinical trials, patients with CAD or PVD were given a recombinant adenovirus that encoded for a protein that contained the terminal half of HIF-1 alpha gene fused to an activator protein. • It was administered either via an IM injection (PVD) or intramyocardial injections (CAD) prior to CABG • No adverse effects were seen but also no reports of efficacy were released. This could be due to the fact that the protein did not contain all of the HIF-1 alpha gene and in turn did not encode for all the activities of the gene.

  9. HIF-1 and Cardiovascular Disease • Another pharmacologic alternative for targeting HIF-1 in cardiovascular disease is the development of drugs that inhibit the hydroxylation of HIF-1. • These drugs either: • 1. chelate Fe, (Fe is present in the center of the hydroxylases) or • 2. compete with the hydroxylases at the binding site

  10. HIF-1 and Cardiovascular Disease • A final alternative would be the use of HIF target gene products as therapeutic agents. • Already been done via cloning of erythropoietin gene and production of recombinant human erythropoietin. • Used in chronic renal failure patients to stimulate RBC production • However administration of a single angiogenic factor such as VEGF fails to stimulate a vascular response. • Benefit of using downstream proteins as therapeutic agents is that they act immediately whereas gene therapy requires more time for trascription and translation of target gene products.

  11. HIF-1 and Cancer • In cancer the physiologic responses to hypoxia aids in disease progression • Tumor vessels are structurally & functionally abnormal and contain areas of severe hypoxia. • This results in HIF-1 over expression, which causes additional angiogenesis, genetic instability, immune evasion, metabolic reprogramming, and invasion, and metastasis.

  12. HIF-1 and Cancer • Hypoxia within the tumor is a major mechanism that activates HIF-1 • Loss of tumor suppressor function or increased oncogene function also activates HIF-1. • HIF-1 regulates a myriad of target genes • However, only a small subset of genes in any given cancer will be regulated by HIF-1 • The role of HIF-1 in a specific cancer can guide possible therapies.

  13. HIF-1 and Cancer • A number of chemotherapy agents are directed at inhibiting HIF-1 • Topotecan • Also cardiac glycosides like Digoxin have been shown to decrease HIF-1 and subsequent tumor growth in mice. • Others are agents aimed at blocking HIF-1 are being investigated

  14. HIF-1 and Pulmonary Hypertension • Pulmonary hypertension is a progressive and often fatal consequence of chronic lung disease • In contrast to systemic arterioles which dilate in order to increase tissue perfusion during hypoxia, pulmonary arterioles constrict to shunt blood away from areas of the lung that are not ventilated • This eventually leads to corpulmonale and progressive hypoxemia.

  15. HIF-1 and Pulmonary Hypertension • HIFs regulate target genes that play major roles in the pathology of pulmonary HTN. • Alveolar hypoxia induces HIF-1 activity in vascular smooth muscle cells and alters the intracellular concentrations of K, Ca, & H ions • This leads to smooth muscle cell hypertrophy, proliferation, depolarization, & contraction and increased pulmonary vascular resistance

  16. HIF-1 and Pulmonary Hypertension • Tibetans live in conditions of chronic hypoxia & they have blunted responses to hypoxia, which prevents the development of pulmonary hypertension. • Gene sequencing has revealed loci encoding HIF-2α, hyroxylases (PHD2), factor inhibiting HIF-1, and HIF target genes as playing a significant role in the adaptation that Tibetans exhibit. • Alters vascular, erythropoeitic, and metabolic responses to hypoxia

  17. Conclusions • HIF-1 is an adaptive response in cardiovascular and peripheral vascular disease • HIF-1 is mal-adaptive in cancer • HIF-1 is also maladaptive in chronic lung disease and pulmonary hypertension. • The targeting of HIFs and its inhibitors and activators offer possible treatment options of these diseases.

More Related